The study of Relationship between Expression of RRM 1 and Effect of gemcitabine-based Chemotherapy in Patients with Advanced NSCLC

Objective To investigate the relationship between genetic polymorphisms of RRM 1 and survival of patients with advanced non-small cell lung cancer(NSCLC) treated with gemcitabine based chemotherapy.Methods 40 cases treated with gemcitabine chemotherapy in patients with advanced non-small cell lung cancer,the branch DNA-liquid chip detection of RRM1 mRNA expression level,curative effect of gemcitabine in advanced lung cancer prediction.Results 23 patients with low expression of RRM1 (57.5％),high expression in 17 cases (42.5％),and low expression in patients with high expression of chemotherapy efficiency,time to disease progression was 78.2％,35.2％,12.4 months and 8.2 months,with a significant difference between two groups (P＜0.05).Conclusion The expression of RRM1 gene could be used to predict the chemotherapy index of advanced non-small cell cancer with gemcitabine platinum. Key words: Branch of the DNA-liquid chip technology;  RRM1 ;  non-small cell lung cancer